23 results  1 of 2 

1 The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
Jihyun An, Hyo Jeong Kang, Eunsil Yu, Han Chu Lee, Ju Hyun Shim
J Liver Cancer.2022;22(1):40-50.   Published online 2022 March 17     DOI: http://dx.doi.org/10.17998/jlc.2022.03.06
      
2 The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
Xiaoyan Sun, Yingnan Feng, Bin Zhang, Wuhao Huang, Xiaoliang Zhao, Hua Zhang, Dongsheng Yue, Changli Wang
Cancer Res Treat.2022;54(4):1017-1029.   Published online 2021 November 23     DOI: http://dx.doi.org/10.4143/crt.2021.1007
      
3 Advances in immune checkpoint inhibitors for hepatocellular carcinoma
Ji Won Han, Su-Hyung Park
J Liver Cancer.2021;21(2):139-145.   Published online 2021 September 30     DOI: http://dx.doi.org/10.17998/jlc.2021.09.24
      
4 Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell–Mediated Tumor Therapy
Yilei Chen, Hongxing Huang, Yin Liu, Zhanghao Wang, Lili Wang, Quanxiao Wang, Yan Zhang, Hua Wang
Cancer Res Treat.2022;54(2):362-374.   Published online 2021 August 3     DOI: http://dx.doi.org/10.4143/crt.2021.424
      
5 Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management
Abdulrazzak Zarifa, Jin Wan Kim, Juan Lopez-Mattei, Nicolas Palaskas, Cezar Iliescu, Peter Y. Kim
Korean Circ J.2021;51(7):579-597.   Published online 2021 May 21     DOI: http://dx.doi.org/10.4070/kcj.2021.0089
      
6 Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
Min Young Lee, Chan-Jeoung Park, Young-Uk Cho, Eunkyoung You, Seongsoo Jang, Eul Ju Seo, Jung-Hee Lee, Dok Hyun Yoon, Cheolwon Suh
Ann Lab Med.2021;41(3):259-267.   Published online 2021 May 1     DOI: http://dx.doi.org/10.3343/alm.2021.41.3.259
      
7 Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center
Young Sok Ji, Se Hoon Park
Cancer Res Treat.2021;53(3):874-880.   Published online 2020 December 7     DOI: http://dx.doi.org/10.4143/crt.2020.1066
      
8 Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
Sun Min Lim, Sang-We Kim, Byoung Chul Cho, Jin Hyung Kang, Myung-Ju Ahn, Dong-Wan Kim, Young-Chul Kim, Jin Soo Lee, Jong-Seok Lee, Sung Yong Lee, Keon Uk Park, Ho Jung An, Eun Kyung Cho, Tae Won Jang, Bong-Seog Kim, Joo-Hang Kim, Sung Sook Lee, Im-II Na, Seung Soo Yoo, Ki Hyeong Lee
Cancer Res Treat.2020;52(4):1112-1119.   Published online 2020 May 15     DOI: http://dx.doi.org/10.4143/crt.2020.245
      
9 Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im, Sang-Jun Ha
Immune Netw.2020;20(1):e2.  Published online 2020 February 20     DOI: http://dx.doi.org/10.4110/in.2020.20.e2
      
10 Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin
Immune Netw.2020;20(1):e8.  Published online 2020 February 10     DOI: http://dx.doi.org/10.4110/in.2020.20.e8
      
11 Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im, Sang-Jun Ha
Immune Netw.2020;20(1):e2.  Published online 2020 February 4     DOI: http://dx.doi.org/10.4110/in.2020.20.e2
      
12 Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin
Immune Netw.2020;20(1):e8.  Published online 2020 February 4     DOI: http://dx.doi.org/10.4110/in.2020.20.e8
      
13 PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
Mst Shanta Islam Tultul, Young-Sang Koh
J Bacteriol Virol.2019;49(4):230-236.   Published online 2019 December 9     DOI: http://dx.doi.org/10.4167/jbv.2019.49.4.230
   
14 Cancer Immunotherapy Related Endocrine Adverse Effects
Hana Kim, Sun Wook Cho, Young Joo Park
Int J Thyroidol.2019;12(2):97-104.   Published online 2019 November 30     DOI: http://dx.doi.org/10.11106/ijt.2019.12.2.97
      
15 Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
Ye Jin Lee, Hak Tae Kim, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Woo Jin Lee
J Korean Med Sci.2019;34(26):e186.  Published online 2019 June 17     DOI: http://dx.doi.org/10.3346/jkms.2019.34.e186
   
16 Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, Domenica Lorusso, Francesco Raspagliesi, Michele Del Vecchio
J Gynecol Oncol.2019;30(6):e94.  Published online 2019 May 13     DOI: http://dx.doi.org/10.3802/jgo.2019.30.e94
      
17 Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators
Minsuk Kwon, Young Joon Choi, Moa Sa, Su-Hyung Park, Eui-Cheol Shin
Immune Netw.2018;18(6):e45.  Published online 2018 December 19     DOI: http://dx.doi.org/10.4110/in.2018.18.e45
      
18 A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis
Hana Kim, Min Joo Kim, Young Shin Song, Sun Wook Cho
Int J Thyroidol.2018;11(2):172-175.   Published online 2018 November 5     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.172
   
19 Immune checkpoint inhibitors for urothelial carcinoma
Hyung Suk Kim, Ho Kyung Seo
Investig Clin Urol.2018;59(5):285-296.   Published online 2018 August 31     DOI: http://dx.doi.org/10.4111/icu.2018.59.5.285
      
20 Immune checkpoint blockade therapy for bladder cancer treatment
Jayoung Kim
Investig Clin Urol.2016;57(Suppl 1):S98-S105.   Published online 2016 May 26     DOI: http://dx.doi.org/10.4111/icu.2016.57.S1.S98
      

 1 of 2